Patient Characteristics and p53 Status, bcl-2 Expression, and MIB-1
| Variables . | No. of Patients (%) . | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| . | p53* . | bcl-2† . | MIB-1 . | . | . | . | . | . | . | ||||||
| . | + (n = 16) . | − (n = 59) . | P2 . | 0/1 (n = 29) . | 2/3 (n = 40) . | P2 . | <80% (n = 51) . | ≥80% (n = 16) . | P2 . | . | . | . | . | . | . |
| Markers | |||||||||||||||
| p53+ | — | — | — | 7 (24) | 8 (20) | .68 | 14 (27) | 2 (13) | .32 | ||||||
| bcl-2+‡ | — | — | — | — | — | — | 34 (68) | 4 (27) | .004 | ||||||
| Histologyρ | |||||||||||||||
| Low-grade | 2 (13) | 13 (87) | 1 (7) | 13 (93) | 12 (92) | 1 (8) | |||||||||
| Progressed low-grade | 4 (17) | 19 (83) | 0.61 | 8 (36) | 14 (64) | .003 | 20 (91) | 2 (9) | .008 | ||||||
| Intermediate-grade | 10 (27) | 27 (73) | 20 (61) | 13 (39) | 19 (59) | 13 (41) | |||||||||
| Clinical features | |||||||||||||||
| Age [median] | [54] | [51] | 1.00 | [49] | [52.5] | .27 | [51] | [53] | .27 | ||||||
| LDH elevated | 11 (69) | 32 (54) | 0.30 | 16 (55) | 24 (60) | .69 | 11 (69) | 32 (54) | .53 | ||||||
| Performance status 2-4 | 12 (75) | 32 (54) | 0.14 | 15 (52) | 25 (63) | .37 | 28 (55) | 10 (63) | .59 | ||||||
| Stage III or IV | 14 (88) | 50 (85) | 1.00 | 24 (83) | 35 (88) | .73 | 47 (92) | 10 (63) | .009 | ||||||
| Extranodal sites >1 | 3 (19) | 14 (24) | 1.00 | 3 (10) | 13 (32) | .031 | 11 (22) | 3 (19) | 1.0 | ||||||
| Mass >10 cm | 6 (38) | 11 (19) | 0.18 | 6 (21) | 9 (23) | .86 | 10 (20) | 4 (25) | .73 | ||||||
| Refractory disease1-155 | 8 (50) | 16 (27) | 0.08 | 8 (28) | 15 (38) | .39 | 17 (33) | 4 (25) | .53 | ||||||
| Prior regimens [median] | [3] | [1] | 0.33 | [1] | [2] | .054 | [2] | [1] | .001 | ||||||
| Variables . | No. of Patients (%) . | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| . | p53* . | bcl-2† . | MIB-1 . | . | . | . | . | . | . | ||||||
| . | + (n = 16) . | − (n = 59) . | P2 . | 0/1 (n = 29) . | 2/3 (n = 40) . | P2 . | <80% (n = 51) . | ≥80% (n = 16) . | P2 . | . | . | . | . | . | . |
| Markers | |||||||||||||||
| p53+ | — | — | — | 7 (24) | 8 (20) | .68 | 14 (27) | 2 (13) | .32 | ||||||
| bcl-2+‡ | — | — | — | — | — | — | 34 (68) | 4 (27) | .004 | ||||||
| Histologyρ | |||||||||||||||
| Low-grade | 2 (13) | 13 (87) | 1 (7) | 13 (93) | 12 (92) | 1 (8) | |||||||||
| Progressed low-grade | 4 (17) | 19 (83) | 0.61 | 8 (36) | 14 (64) | .003 | 20 (91) | 2 (9) | .008 | ||||||
| Intermediate-grade | 10 (27) | 27 (73) | 20 (61) | 13 (39) | 19 (59) | 13 (41) | |||||||||
| Clinical features | |||||||||||||||
| Age [median] | [54] | [51] | 1.00 | [49] | [52.5] | .27 | [51] | [53] | .27 | ||||||
| LDH elevated | 11 (69) | 32 (54) | 0.30 | 16 (55) | 24 (60) | .69 | 11 (69) | 32 (54) | .53 | ||||||
| Performance status 2-4 | 12 (75) | 32 (54) | 0.14 | 15 (52) | 25 (63) | .37 | 28 (55) | 10 (63) | .59 | ||||||
| Stage III or IV | 14 (88) | 50 (85) | 1.00 | 24 (83) | 35 (88) | .73 | 47 (92) | 10 (63) | .009 | ||||||
| Extranodal sites >1 | 3 (19) | 14 (24) | 1.00 | 3 (10) | 13 (32) | .031 | 11 (22) | 3 (19) | 1.0 | ||||||
| Mass >10 cm | 6 (38) | 11 (19) | 0.18 | 6 (21) | 9 (23) | .86 | 10 (20) | 4 (25) | .73 | ||||||
| Refractory disease1-155 | 8 (50) | 16 (27) | 0.08 | 8 (28) | 15 (38) | .39 | 17 (33) | 4 (25) | .53 | ||||||
| Prior regimens [median] | [3] | [1] | 0.33 | [1] | [2] | .054 | [2] | [1] | .001 | ||||||
Statistically significant P values are shown in boldface.
p53+, mutation or overexpression.
Expression level is graded 0, 1, 2, and 3 as described in Materials and Methods.
bcl-2+, expression 2 or 3; MIB-1 <80%, n = 50; MIB-1 ≥80%, n = 15.
ρ Low-grade includes follicular small cleaved (n = 3), follicular mixed (n = 5), small lymphocytic (n = 3), diffuse small cleaved (n = 1), and mantle cell (n = 3); progressed low-grade includes (most aggressive histology) diffuse large cell/immunoblastic (n = 11), follicular large cell (n = 1), diffuse mixed (n = 9), and mantle cell blastic (n = 2); and intermediate-grade includes diffuse large cell/immunoblastic (n = 35) and diffuse mixed (n = 2).
No response to last administered chemotherapy.